Are Wall Street Analysts Bullish on Quest Diagnostics Stock?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 24 2025
0mins
Source: NASDAQ.COM
Company Performance: Quest Diagnostics (DGX) has outperformed the S&P 500 and SPDR S&P Health Care Services ETF over the past year, with a 35.9% increase in stock value compared to the broader market's 20.7% rise, driven by consistent demand, innovation, and strategic acquisitions.
Analyst Ratings and Expectations: Analysts maintain a "Moderate Buy" consensus on DGX stock, with an adjusted EPS forecast of $9.70 for fiscal 2025, and Mizuho Financial has raised its price target to $178, indicating potential upside from current levels.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MFG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MFG
Wall Street analysts forecast MFG stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 9.760
Low
38.88
Averages
38.88
High
38.88
Current: 9.760
Low
38.88
Averages
38.88
High
38.88
About MFG
Mizuho Financial Group Inc is a Japan-based company mainly engaged in the banking, trust banking, securities, and other financial services. The Company operates through five business segments: Retail & Business Corporations Company (RBC), Corporate & Investment Banking Company (CIBC), Global Corporate & Investment Banking Company (GCIBC), Global Markets Company (GMC), and Asset Management Company (AMC). The CIBC segment operates for clients of large corporate corporations, financial corporations and public corporations in Japan. The GCIBC segment operates for clients of overseas-affiliated Japanese companies and non-Japanese companies. The GMC segment is engaged in investment business in interest rates, equity, among others. The AMC segment is engaged in the development and provision of products that meet the asset management needs of clients from individuals to institutional investors.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CVS Health Stock Surges on Medicare Developments
- Stock Recovery: After a rough start to 2026, CVS Health shares have surged over 25% recently due to promising Medicare-related developments, indicating a strong market rebound that boosts investor confidence.
- Analyst Target Increase: Mizuho analyst Ann Hynes raised CVS's price target from $110 to $115, presenting about a 13% upside from the current price of $100.68, reflecting optimistic market expectations for CVS's future performance.
- Investor Sentiment Shift: As the stock price rises, investors are increasingly confident that CVS can continue to exceed expectations, moving beyond merely anticipating “better than expected” results, which could drive further price increases.
- Valuation Potential: Currently trading at a forward P/E of 13.8, if CVS reaches $115 with projected earnings of $7.43 per share in 2026, the P/E would rise to 15.5, suggesting that a revaluation could push the stock price closer to $150.
See More
Mizuho Raises CVS Price Target to $115
- Price Target Increase: Mizuho analyst Ann Hynes raised CVS Health's price target from $110 to $115, implying a potential upside of approximately 13%, reflecting market optimism regarding CVS's future performance.
- Stock Recovery: After a rough start to 2026, CVS Health's shares have surged over 25%, indicating increased investor confidence in the company's promising developments related to Medicare, suggesting it may continue to exceed market expectations.
- Valuation Potential: Currently trading at about 13.8 times forward earnings, if CVS's stock rises to $115, based on a forecasted earnings of $7.43 per share for 2026, it would imply a forward multiple of 15.5, showcasing CVS's competitive edge and growth potential in the healthcare sector.
- Market Perception Shift: As CVS is recognized as a diversified healthcare services company, market understanding of its valuation is aligning more closely with that of UnitedHealth Group, and if CVS's forward multiple rises to as high as 20 times, its stock price could approach $150, further solidifying its status as a blue-chip stock.
See More
D-Wave Quantum Stock Price Target Raised by Analysts
- Analyst Price Target Increase: Mizuho analyst Vijay Rakesh raised the price target for D-Wave Quantum from $29 to $35, reflecting an optimistic outlook on the company's future growth, implying a potential upside of over 20%.
- Positive Market Reaction: Following the analyst's bullish outlook, D-Wave Quantum stock surged 13.6% at the start of trading, indicating strong investor interest and confidence in the quantum computing sector.
- Extended Technology Roadmap: D-Wave Quantum aims to deliver a 17-physical-qubit system by 2026 and scale to a 100-logical-qubit system capable of over 1 million operations by 2032, with successful achievement of these goals likely to bolster investor confidence further.
- Caution for Investors: While analysts are generally optimistic about D-Wave Quantum's prospects, potential investors should focus on the company's actual achievements rather than solely relying on analyst predictions to ensure the feasibility of its 2030 and 2032 targets.
See More
D-Wave Quantum Stock Soars 13.6% on Bullish Analyst Outlook
- Analyst Optimism: Mizuho analyst Vijay Rakesh raised the price target for D-Wave Quantum from $29 to $35, reflecting strong market confidence in the quantum computing company and implying over 20% upside potential for the stock.
- Industry Leadership: With a market cap of $8.7 billion and a current stock price of $26.53, D-Wave Quantum demonstrates its leading position in the quantum computing sector, having fluctuated between $12.75 and $46.75 over the past 52 weeks, indicating strong growth expectations.
- Technological Advancement Goals: The company aims to achieve 10 logical qubits by 2030 and expand to 100 logical qubits by 2032, with the capability to perform over 1 million operations, providing investors with confidence in its long-term growth trajectory.
- Investor Considerations: While analysts are generally bullish on D-Wave Quantum's prospects, potential investors should focus on the company's actual progress towards its 2030 and 2032 targets to ensure sound investment decisions.
See More
Analysts Bullish on Cerebras Stock Outlook
- Analyst Coverage Initiated: Several analysts initiated coverage on Cerebras this week, with Barclays assigning an overweight rating and a $280 price target, reflecting strong market confidence in the AI company.
- Stock Price Rebound: After a decline of over 15% last week, Cerebras shares have rebounded by 10.2%, indicating a positive investor response to the bullish analyst outlook.
- Future Revenue Expectations: Analysts project that Cerebras could generate $6 billion in revenue by 2028, significantly higher than the $510 million reported in 2025, highlighting the company's substantial growth potential in the AI sector.
- Strong Market Demand: A Craig-Hallum analyst noted that Cerebras's leading position in AI inference speed has attracted interest from OpenAI and Amazon's AWS, further solidifying its competitive edge in the market.
See More
S&P Global Spins Off Mobility Business into Standalone Company
- Spinoff Announcement: S&P Global is spinning off its Mobility business into a standalone entity named Mobility Global, which will begin trading on the NYSE under the ticker MBGL on July 1, allowing S&P to concentrate more resources on its core operations and enhance its competitive edge in the market.
- Shareholder Benefits: As part of the spinoff, shareholders will receive one share of Mobility Global common stock for each share of S&P Global common stock held as of the close on June 15, with the distribution expected to be effective on July 1, thereby increasing shareholder value and engagement.
- Financial Performance: The Mobility segment generated $454 million in revenue last quarter, reflecting an 8% year-over-year increase, and while it remains the smallest business unit, its operating profit grew by 9%, indicating potential for growth post-spinoff.
- Market Outlook: Analysts are bullish on the spinoff, with 93% rating S&P Global stock as a buy and projecting a 28% upside over the next 12 months, showcasing strong market confidence in S&P Global's future growth trajectory despite an 18% decline in stock price this year.
See More
CVS Health Stock Surges on Medicare Developments
- Stock Recovery: After a rough start to 2026, CVS Health shares have surged over 25% recently due to promising Medicare-related developments, indicating a strong market rebound that boosts investor confidence.
- Analyst Target Increase: Mizuho analyst Ann Hynes raised CVS's price target from $110 to $115, presenting about a 13% upside from the current price of $100.68, reflecting optimistic market expectations for CVS's future performance.
- Investor Sentiment Shift: As the stock price rises, investors are increasingly confident that CVS can continue to exceed expectations, moving beyond merely anticipating “better than expected” results, which could drive further price increases.
- Valuation Potential: Currently trading at a forward P/E of 13.8, if CVS reaches $115 with projected earnings of $7.43 per share in 2026, the P/E would rise to 15.5, suggesting that a revaluation could push the stock price closer to $150.
See More
Mizuho Raises CVS Price Target to $115
- Price Target Increase: Mizuho analyst Ann Hynes raised CVS Health's price target from $110 to $115, implying a potential upside of approximately 13%, reflecting market optimism regarding CVS's future performance.
- Stock Recovery: After a rough start to 2026, CVS Health's shares have surged over 25%, indicating increased investor confidence in the company's promising developments related to Medicare, suggesting it may continue to exceed market expectations.
- Valuation Potential: Currently trading at about 13.8 times forward earnings, if CVS's stock rises to $115, based on a forecasted earnings of $7.43 per share for 2026, it would imply a forward multiple of 15.5, showcasing CVS's competitive edge and growth potential in the healthcare sector.
- Market Perception Shift: As CVS is recognized as a diversified healthcare services company, market understanding of its valuation is aligning more closely with that of UnitedHealth Group, and if CVS's forward multiple rises to as high as 20 times, its stock price could approach $150, further solidifying its status as a blue-chip stock.
See More
D-Wave Quantum Stock Price Target Raised by Analysts
- Analyst Price Target Increase: Mizuho analyst Vijay Rakesh raised the price target for D-Wave Quantum from $29 to $35, reflecting an optimistic outlook on the company's future growth, implying a potential upside of over 20%.
- Positive Market Reaction: Following the analyst's bullish outlook, D-Wave Quantum stock surged 13.6% at the start of trading, indicating strong investor interest and confidence in the quantum computing sector.
- Extended Technology Roadmap: D-Wave Quantum aims to deliver a 17-physical-qubit system by 2026 and scale to a 100-logical-qubit system capable of over 1 million operations by 2032, with successful achievement of these goals likely to bolster investor confidence further.
- Caution for Investors: While analysts are generally optimistic about D-Wave Quantum's prospects, potential investors should focus on the company's actual achievements rather than solely relying on analyst predictions to ensure the feasibility of its 2030 and 2032 targets.
See More
D-Wave Quantum Stock Soars 13.6% on Bullish Analyst Outlook
- Analyst Optimism: Mizuho analyst Vijay Rakesh raised the price target for D-Wave Quantum from $29 to $35, reflecting strong market confidence in the quantum computing company and implying over 20% upside potential for the stock.
- Industry Leadership: With a market cap of $8.7 billion and a current stock price of $26.53, D-Wave Quantum demonstrates its leading position in the quantum computing sector, having fluctuated between $12.75 and $46.75 over the past 52 weeks, indicating strong growth expectations.
- Technological Advancement Goals: The company aims to achieve 10 logical qubits by 2030 and expand to 100 logical qubits by 2032, with the capability to perform over 1 million operations, providing investors with confidence in its long-term growth trajectory.
- Investor Considerations: While analysts are generally bullish on D-Wave Quantum's prospects, potential investors should focus on the company's actual progress towards its 2030 and 2032 targets to ensure sound investment decisions.
See More
Analysts Bullish on Cerebras Stock Outlook
- Analyst Coverage Initiated: Several analysts initiated coverage on Cerebras this week, with Barclays assigning an overweight rating and a $280 price target, reflecting strong market confidence in the AI company.
- Stock Price Rebound: After a decline of over 15% last week, Cerebras shares have rebounded by 10.2%, indicating a positive investor response to the bullish analyst outlook.
- Future Revenue Expectations: Analysts project that Cerebras could generate $6 billion in revenue by 2028, significantly higher than the $510 million reported in 2025, highlighting the company's substantial growth potential in the AI sector.
- Strong Market Demand: A Craig-Hallum analyst noted that Cerebras's leading position in AI inference speed has attracted interest from OpenAI and Amazon's AWS, further solidifying its competitive edge in the market.
See More
S&P Global Spins Off Mobility Business into Standalone Company
- Spinoff Announcement: S&P Global is spinning off its Mobility business into a standalone entity named Mobility Global, which will begin trading on the NYSE under the ticker MBGL on July 1, allowing S&P to concentrate more resources on its core operations and enhance its competitive edge in the market.
- Shareholder Benefits: As part of the spinoff, shareholders will receive one share of Mobility Global common stock for each share of S&P Global common stock held as of the close on June 15, with the distribution expected to be effective on July 1, thereby increasing shareholder value and engagement.
- Financial Performance: The Mobility segment generated $454 million in revenue last quarter, reflecting an 8% year-over-year increase, and while it remains the smallest business unit, its operating profit grew by 9%, indicating potential for growth post-spinoff.
- Market Outlook: Analysts are bullish on the spinoff, with 93% rating S&P Global stock as a buy and projecting a 28% upside over the next 12 months, showcasing strong market confidence in S&P Global's future growth trajectory despite an 18% decline in stock price this year.
See More
